3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Conditions
Hospice
1
Interventions
pembrolizumab
304
Carboplatin
155
Nivolumab
155
Cisplatin
140
Cyclophosphamide
132
Paclitaxel
128
Magnetic Resonance Spectroscopy
98
Specimen Handling
95
Radiotherapy
91
Gemcitabine
87
Dexamethasone
85
Biopsy
81
Ipilimumab
78
Doxorubicin
76
Docetaxel
75
Rituximab
70
Etoposide
67
atezolizumab
62
durvalumab
61
Radiation
60
Lenalidomide
59
Pemetrexed
58
Taxes
57
Bevacizumab
55
Prednisone
55
fludarabine
54
olaparib
54
Vincristine
50
Cytarabine
48
Fluorouracil
48
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Psychotherapy
×
1 year
×
Clear all
NCT04950608
2026-02-17
PATH
Dana-Farber Cancer Institute
Phase 2
Completed
15 enrolled
26 charts